PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
Clinical trials for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) trials appear
Sign up with your email to follow new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Hard-to-Treat blood cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called NX-2127 in adults with certain blood cancers (like CLL or lymphoma) that have returned or not improved after other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About …
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 06:18 UTC
-
New hope for aggressive brain lymphoma: 3-drug combo enters phase 2 trial
Disease control Recruiting nowThis study tests a combination of three drugs (pomalidomide, an anti-PD-1 antibody, and selinexor) in people whose primary central nervous system lymphoma has come back or not responded to prior treatment. The goal is to see if this combination can shrink or eliminate tumors. Abo…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
Phase: PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated May 17, 2026 06:18 UTC
-
New drug targets Hard-to-Treat blood cancers in early trial
Disease control Recruiting nowThis study tests an experimental drug called NX-5948 in adults with certain blood cancers (like CLL or lymphoma) that have come back or stopped responding to treatment. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to find a safe dose …
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 06:16 UTC
-
New hope for brain lymphoma patients with targeted drug cocktail
Disease control Recruiting nowThis study tests a combination of four drugs (PD-1 inhibitor, rituximab, methotrexate, and orelabrutinib) in 50 adults with newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this treatment can stop the cancer from growing for at least one year. Pa…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug cocktail takes on recurrent brain cancer
Disease control Recruiting nowThis early-phase trial is testing whether combining two drugs, epcoritamab and ibrutinib, is safe for people with central nervous system (CNS) lymphoma that has come back or not responded to treatment. About 26 adults with this rare brain cancer will take part. The main goal is t…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:15 UTC
-
New study hunts for clues in blood to unlock brain lymphoma mysteries
Knowledge-focused Recruiting nowThis study compares blood samples from people with primary central nervous system lymphoma (PCNSL), those with a related lymphoma outside the brain, and healthy volunteers. Researchers will look for unique chemical and immune cell patterns that could help tell these conditions ap…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
Sponsor: Ting YANG • Aim: Knowledge-focused
Last updated May 05, 2026 11:55 UTC